Skip to content

EU post-market obligations for drugs and biologics

Oak
A circular laboratory instrument holds rings of tiny glowing vials around a turning lens, a few vials amber and raised.

Once a medicinal product is placed on the EU market, the marketing authorisation holder must operate a pharmacovigilance system, record and report suspected adverse reactions, submit periodic safety update reports and keep a risk management system in place.1 The holder must also forward any new information that could alter the assessment of benefits and risks and keep the product information aligned with current scientific knowledge.2 The substantive obligations sit in Title IX of Directive 2001/83/EC. Regulation (EC) No 726/2004 applies those obligations to centrally authorised products and adds requirements specific to them.

The pharmacovigilance system the holder must operate

Article 104 of Directive 2001/83/EC requires the marketing authorisation holder to operate a pharmacovigilance system equivalent to the system a Member State operates under Article 101(1).1 Through that system the holder evaluates all information scientifically, considers options for risk minimisation and prevention and takes appropriate measures.1 The holder must perform a regular audit of the system, place a note on the main audit findings in the pharmacovigilance system master file and ensure that a corrective action plan is prepared and implemented on the basis of those findings.1 The note may be removed once the corrective actions have been fully implemented.1

Article 104(3) sets out five elements of the system. The holder must have permanently and continuously at his disposal an appropriately qualified person responsible for pharmacovigilance, maintain a pharmacovigilance system master file and make it available on request, and operate a risk management system for each medicinal product.1 The holder must monitor the outcome of the risk minimisation measures contained in the risk management plan or laid down as conditions of the authorisation under Articles 21a, 22 or 22a.1 The holder must also update the risk management system and monitor pharmacovigilance data to determine whether new risks have arisen, whether existing risks have changed or whether the benefit-risk balance has changed.1

The qualified person must reside and operate in the Union and is responsible for the establishment and maintenance of the pharmacovigilance system.1 The holder submits that person’s name and contact details to the competent authority and to the Agency.1 A derogation applies where the marketing authorisation is granted by the competent authority of the United Kingdom in respect of Northern Ireland: the qualified person may then reside and operate in parts of the United Kingdom other than Northern Ireland.1 That derogation does not apply where the holder already had a qualified person residing and operating in the Union on 20 April 2022.1 National competent authorities may separately request the nomination of a national contact person for pharmacovigilance reporting to the qualified person.1

For centrally authorised products, Article 21 of Regulation (EC) No 726/2004 applies the Article 104 obligations in full, with one carve-out.2 Holders of marketing authorisations granted before 2 July 2012 are not required, by derogation from Article 104(3)(c), to operate a risk management system for each medicinal product.2 The Agency may nonetheless impose that obligation where there are concerns about risks affecting the benefit-risk balance, and must then also require a detailed description of the intended system.2 The imposition must be justified and notified in writing with a timeframe for submission.2 The holder may request an opportunity to present written observations within 30 days of receiving the notification.2 The Commission then withdraws or confirms the obligation, and where it confirms, the authorisation is varied to include the measures as conditions under Article 9(4)(ca).2

Recording and reporting suspected adverse reactions

Article 107 of Directive 2001/83/EC governs case reporting. The holder must record all suspected adverse reactions arising in the Union or in third countries that are brought to his attention, whether reported spontaneously by patients or healthcare professionals or occurring in a post-authorisation study.1 Those reports must be accessible at a single point within the Union.1 Suspected adverse reactions occurring in a clinical trial are recorded and reported under Directive 2001/20/EC instead.1 The holder must not refuse to consider reports received electronically or by other appropriate means from patients and healthcare professionals.1

Two deadlines apply for submission to the EudraVigilance database. Serious suspected adverse reactions occurring in the Union and in third countries must be submitted electronically within 15 days of the day the holder gained knowledge of the event.1 Non-serious suspected adverse reactions occurring in the Union must be submitted within 90 days of that day.1 The 90-day obligation covers all non-serious suspected adverse reactions that occur in the Union.1 For active substances on the list of publications monitored by the Agency under Article 27 of Regulation (EC) No 726/2004, the holder is not required to report the suspected adverse reactions recorded in that listed literature, and must monitor all other medical literature and report what it contains.1 The holder must establish procedures to obtain accurate and verifiable data for scientific evaluation, collect follow-up information and submit updates to EudraVigilance.1 The holder must collaborate with the Agency and Member States in detecting duplicate reports.1

Periodic safety update reports

Article 107b requires the holder to submit periodic safety update reports to the Agency electronically.1 Each report contains summaries of data relevant to the benefits and risks of the product, including the results of all studies and a consideration of their potential impact on the authorisation.1 It also contains a scientific evaluation of the benefit-risk balance, based on all available data including data from clinical trials in unauthorised indications and populations.1 The third element is all data on sales volume and any data the holder holds on prescription volume, including an estimate of the population exposed.1 The Agency makes the reports available to national competent authorities, the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use and the coordination group through the repository under Article 25a of Regulation (EC) No 726/2004.1

Holders of authorisations for generic products under Article 10(1), well-established use products under Article 10a, and registrations under Articles 14 or 16a submit periodic safety update reports only in two cases.1 The first is where the obligation is a condition of the authorisation under Article 21a or Article 22.1 The second is where a competent authority requests reports because of concerns relating to pharmacovigilance data or because reports on an active substance are lacking.1

Frequency, Union reference dates and the legacy schedule

Article 107c(1) provides that the frequency of submission is specified in the marketing authorisation, with dates calculated from the date of authorisation.1 A default schedule applies to authorisations granted before 21 July 2012 where frequency and dates are not a condition of the authorisation.1 Under that schedule reports are submitted immediately on request, or at least every six months following authorisation until the product is placed on the market.1 Once the product is on the market, reports are submitted at least every six months during the first two years, once a year for the following two years and at three-yearly intervals thereafter.1 For centrally authorised products, Article 28(2) of Regulation (EC) No 726/2004 applies the equivalent transitional arrangement to authorisations granted before 2 July 2012.2

Where different authorisations cover the same active substance or combination, the frequency and dates may be harmonised to allow a single assessment under a work-sharing procedure, with a Union reference date from which submission dates are calculated.1 The Committee for Medicinal Products for Human Use sets the harmonised frequency where at least one authorisation was granted centrally, and the coordination group does so in other cases, each after consulting the Pharmacovigilance Risk Assessment Committee.1 The Union reference date is the date of the first authorisation in the Union of a product containing that substance, or the earliest known authorisation date where that cannot be ascertained.1 A holder may request determination of a Union reference date or a change of frequency in writing on grounds of public health, avoidance of duplicate assessment or international harmonisation.1 Any resulting change in dates or frequency takes effect six months after the Agency publishes it, and the holder submits a variation application accordingly.1

How the reports are assessed for centrally authorised products

Article 28(3) of Regulation (EC) No 726/2004 sets the assessment timetable. A rapporteur appointed by the Pharmacovigilance Risk Assessment Committee prepares an assessment report within 60 days of receipt of the periodic safety update report and sends it to the Agency and committee members, and the Agency sends it to the holder.2 The holder and committee members may submit comments within 30 days of receiving the assessment report.2 The rapporteur updates the report within 15 days of those comments and forwards it to the committee, which adopts it at its next meeting and issues a recommendation noting any divergent positions.2

Where the assessment report recommends action on the authorisation, the Committee for Medicinal Products for Human Use considers it within 30 days and adopts an opinion on maintenance, variation, suspension or revocation, including an implementation timetable.2 Where that opinion differs from the committee recommendation, it must be accompanied by a detailed explanation of the scientific grounds.2 Where regulatory action is necessary, the Commission adopts a decision.2 Final recommendations, opinions and decisions are made public through the European medicines web-portal.2

Keeping the dossier and product information current

Article 16 of Regulation (EC) No 726/2004 imposes a continuing duty to update. The holder must take account of scientific and technical progress in the methods of manufacture and control and introduce the changes needed for the product to be manufactured and checked by generally accepted scientific methods, applying for the corresponding variations.2 The holder must forthwith provide the Agency, the Commission and the Member States with any new information that might entail amendment of the dossier particulars or documents.2 The holder must in particular inform the Agency and the Commission forthwith of any prohibition or restriction imposed by the competent authorities of any country in which the product is marketed.2

The information to be provided covers both positive and negative results of clinical trials or other studies in all indications and populations, whether or not covered by the authorisation, and data on use outside the terms of the authorisation.2 The holder must keep the product information up to date with current scientific knowledge, including conclusions and recommendations published through the European medicines web-portal.2 The Agency may at any time ask the holder to forward data showing that the benefit-risk balance remains favourable, and the holder must answer fully and promptly.2 The Agency may also request a copy of the pharmacovigilance system master file, which the holder must submit no later than seven days after receipt of the request.2

Additional monitoring and safety announcements

Article 23 of Regulation (EC) No 726/2004 requires the Agency to set up, maintain and publish a list of medicinal products subject to additional monitoring.2 The list covers products authorised in the Union containing a new active substance that was not contained in any product authorised in the Union on 1 January 2011.2 It also covers any biological medicinal product not caught by that criterion that was authorised after 1 January 2011.2 It further covers products authorised subject to specified conditions under Regulation (EC) No 726/2004 or Directive 2001/83/EC.2 The list includes an electronic link to the product information and to the summary of the risk management plan.2

The summary of product characteristics and the package leaflet of a listed product must carry the statement “This medicinal product is subject to additional monitoring”, preceded by a black symbol and followed by a standardised explanatory sentence.2 For new active substances and biologicals, the Agency removes the product from the list five years after the Union reference date under Article 107c(5) of Directive 2001/83/EC.2 For conditional entries, removal follows once the conditions have been fulfilled.2 Article 22 applies the obligations in Article 106a(1) of the Directive to safety announcements concerning centrally authorised products.2

Questions people also ask

How quickly must a serious suspected adverse reaction be reported in the EU?

Article 107(3) of Directive 2001/83/EC requires the marketing authorisation holder to submit information on all serious suspected adverse reactions occurring in the Union and in third countries to the EudraVigilance database within 15 days following the day the holder gained knowledge of the event.1 Non-serious suspected adverse reactions occurring in the Union must be submitted within 90 days of that day.1

Do generic medicines require periodic safety update reports?

Under Article 107b(3) of Directive 2001/83/EC, holders of authorisations for products referred to in Article 10(1) or Article 10a submit periodic safety update reports in two situations only.1 The first is where the obligation is laid down as a condition of the authorisation under Article 21a or Article 22. The second is where a competent authority requests them because of concerns relating to pharmacovigilance data or because reports on the active substance are lacking.1

Which medicines are subject to additional monitoring?

Article 23(1) of Regulation (EC) No 726/2004 lists products containing a new active substance that was not in any Union-authorised product on 1 January 2011, and any other biological medicinal product authorised after that date.2 It also lists products authorised subject to certain conditions under either instrument. A listed product carries a statement in its summary of product characteristics and package leaflet preceded by a black symbol.2

Where must the qualified person responsible for pharmacovigilance be based?

Article 104(3) of Directive 2001/83/EC requires the qualified person to reside and operate in the Union.1 That person is responsible for the establishment and maintenance of the pharmacovigilance system, and the holder submits the name and contact details to the competent authority and the Agency.1 A derogation allows a qualified person for a Northern Ireland authorisation to reside and operate elsewhere in the United Kingdom in defined circumstances.1

How long does the holder have to supply the pharmacovigilance system master file on request?

For centrally authorised products, Article 16(3a) of Regulation (EC) No 726/2004 allows the Agency to request a copy of the pharmacovigilance system master file at any time, and the holder must submit it no later than seven days after receipt of the request.2 Article 104(3)(b) of Directive 2001/83/EC separately requires the holder to maintain the master file and make it available on request.1

Footnotes

  1. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Consolidated version of 2025-01-01. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083-20250101 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33 ↩34 ↩35 ↩36 ↩37 ↩38 ↩39 ↩40 ↩41 ↩42 ↩43 ↩44 ↩45 ↩46 ↩47 ↩48

  2. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Consolidated version of 2022-01-28. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02004R0726-20220128 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33 ↩34

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.